‘Twincretin’ Weight Loss Scales Up Cardiometabolic Gains
A post hoc analysis of the SRMOUNT-1 study finds weight loss from the use of tirzepatide was associated with strong benefits in measures of cardiometabolic health. Medscape Medical News
Amanda Bynes Steps Out After Revealing She’s Using Ozempic And Why, Sparking Mixed Reactions
Amanda Bynes was spotted out and about in Los Angeles after telling fans she was starting Ozempic. The former child star, 39, candidly spoke about her current weight and how she’s taking the blockbuster weight-loss medication to help her slim down. Fans had mixed reactions after she shared the exact reason why she was turning […]
Real‐world insights into incretin‐based therapy: Associations between changes in taste perception and appetite regulation in individuals with obesity and overweight: A cross‐sectional study
Abstract Aims This cross-sectional study examined associations between self-reported taste perception changes and appetite-related outcomes in individuals with obesity treated with glucagon-like peptide-1 receptor agonist (GLP-1 RAS) or dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 RAS in real-world conditions. Materials and Methods Four hundred and eleven adults on Wegovy® (n = 217), Ozempic® (n = 148) and Mounjaro® (n = 46) completed an […]
The effects of anti‐obesity medications on bone metabolism: A critical appraisal
Abstract The development of novel sophisticated medications that induce weight loss has revolutionized the management of people living with obesity (PwO). However, when body weight is reduced, muscle and bone are lost along with fat. In the present review, we quote and discuss existing evidence on the effects of the major anti-obesity medications on bone […]
Tirzepatide and cardiometabolic parameters in obesity: Summary of current evidence
Abstract Globally, cardiovascular diseases (CVDs) account for around one-third of all deaths. Clinical trial evidence suggests that treatment of people with obesity or type 2 diabetes (T2D) and CVD with glucagon-like peptide-1 (GLP-1) receptor agonists reduces the risk of major adverse cardiovascular events, heart failure outcomes and all-cause mortality. Tirzepatide is a once-weekly, dual glucose-dependent […]
Novo Nordisk Fast-Tracks Amycretin to Phase 3 for Obesity Treatment
Novo Nordisk (NYSE:NVO) is one of the most active stocks to buy according to analysts. On June 20, Novo Nordisk announced that its investigational obesity treatment, amycretin, will advance directly to Phase 3 clinical development. The decision is based on promising results from two early-phase clinical trials: one for a once-weekly subcutaneous formulation and another […]
LifeMD: An Overlooked GLP-1 Beneficiary
Post Content
These are the top 10 emerging technologies of 2025, according to the World Economic Forum
Breakthroughs happen all the time in the tech world, but only a select few manage to make a lasting impact. Predicting which innovations will shape the future is always a challenge. On Tuesday, the World Economic Forum (WEF) released its list of the top 10 emerging technologies of 2025, highlighting those expected to influence global […]
GLP-1 Agonists: Uses, Mechanism, and Side Effects
https://my.clevelandclinic.org/health/treatments/13901-glp-1-agonists The provided text from the Cleveland Clinic offers a comprehensive overview of GLP-1 agonists, a class of medications primarily used to manage Type 2 diabetes and obesity. It explains how these injectable drugs mimic a natural hormone to regulate blood sugar, slow digestion, and increase feelings of fullness, leading to potential weight loss. The source lists various approved GLP-1 agonists and their typical administration frequencies, […]
Semaglutide Shows Benefits for PAD Across T2D Subgroups
A post-hoc analysis of STRIDE confirms the benefit of GLP-1 RA in patients with peripheral arterial disease and type 2 diabetes, but more research is needed in those without diabetes. Medscape Medical News